IMRX and TEVA Related Headlines
Go Back- Immuneering reports 17.3-month survival in pancreatic cancer trial
- Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
- Immuneering reports Q1 2026 financial results and clinical updates
- Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
- Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
- Immuneering schedules call to discuss pancreatic cancer trial data
- Immuneering schedules call to discuss pancreatic cancer trial data
- Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
- Immuneering prices $200 million stock offering with Sanofi participation
- Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
IMRX and TEVA Related Press Releases
Go Back- Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
- Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
- Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
- Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
- Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
IMRX and TEVA Related SEC Filings
Go Back- Form 8-K Immuneering Corp For: Jun 01
- Form 10-Q Immuneering Corp For: Mar 31
- Form 8-K Immuneering Corp For: May 15
- Form DEFA14A Immuneering Corp
- Form DEF 14A Immuneering Corp For: Apr 20
- Form 4 Immuneering Corp For: Mar 13 Filed by: Neufeld Leah R
- Form 10-K Immuneering Corp For: Dec 31
- Form 8-K Immuneering Corp For: Mar 06
- Form 4 Immuneering Corp For: Feb 03 Filed by: Bookman Michael
- Form 4 Immuneering Corp For: Feb 03 Filed by: Brakewood Harold Eugene
- Form 4 Immuneering Corp For: Feb 03 Filed by: Hall Brett Matthew
- Form 4 Immuneering Corp For: Feb 03 Filed by: Matushansky Igor
- Form 4 Immuneering Corp For: Feb 03 Filed by: Morales Mallory
- Form 4 Immuneering Corp For: Feb 03 Filed by: Neufeld Leah R
- Form 4 Immuneering Corp For: Feb 03 Filed by: Zeskind Benjamin J.
- Form SCHEDULE 13G/A Immuneering Corp Filed by: Zeskind Benjamin J.
- Form 4 Immuneering Corp For: Jan 16 Filed by: Brakewood Harold Eugene
- Form 4 Immuneering Corp For: Jan 15 Filed by: Schall Thomas J.
- Form 4 Immuneering Corp For: Jan 15 Filed by: Hall Brett Matthew
- Form SCHEDULE 13G/A Immuneering Corp Filed by: Empery Asset Management, LP
- Form 4 Immuneering Corp For: Jan 13 Filed by: Neufeld Leah R
- Form 4 Immuneering Corp For: Jan 12 Filed by: Feinberg Peter
- Form 8-K Immuneering Corp For: Jan 07
- Form 4 Immuneering Corp For: Jan 01 Filed by: KEATING LAURIE
- Form 4 Immuneering Corp For: Jan 01 Filed by: Feinberg Peter
- Form 10-Q Immuneering Corp For: Sep 30
- Form 8-K Immuneering Corp For: Nov 12
- Form SCHEDULE 13G Immuneering Corp Filed by: Empery Asset Management, LP
- Form SCHEDULE 13G Immuneering Corp Filed by: FMR LLC
- Form 4 Immuneering Corp For: Oct 03 Filed by: Feinberg Peter
- Form SCHEDULE 13G Immuneering Corp Filed by: HBM Healthcare Investments (Cayman) Ltd.
- Form 4 Immuneering Corp For: Oct 01 Filed by: Morales Mallory
- Form 4 Immuneering Corp For: Oct 01 Filed by: Neufeld Leah R
- Form 4 Immuneering Corp For: Oct 01 Filed by: Bookman Michael
- Form 4 Immuneering Corp For: Sep 30 Filed by: Feinberg Peter
- Form 4 Immuneering Corp For: Sep 29 Filed by: Feinberg Peter
- Form 424B5 Immuneering Corp
- Form 8-K Immuneering Corp For: Sep 24
- Form FWP Immuneering Corp Filed by: Immuneering Corp
- Form FWP Immuneering Corp Filed by: Immuneering Corp
- Form 424B5 Immuneering Corp
- Form 8-K Immuneering Corp For: Sep 24
- Form 144 Immuneering Corp Filed by: BERMAN ANN E
- Form 4 Immuneering Corp For: Sep 15 Filed by: Neufeld Leah R
- Form 4 Immuneering Corp For: Sep 15 Filed by: Morales Mallory
- Form 4 Immuneering Corp For: Sep 15 Filed by: Hall Brett Matthew
- Form D Immuneering Corp
- Form EFFECT Immuneering Corp
- Form 424B3 Immuneering Corp
- Form S-3 Immuneering Corp
- Form 8-K Immuneering Corp For: Aug 21
- Form EFFECT Immuneering Corp
- Form S-3 Immuneering Corp
- Form 10-Q Immuneering Corp For: Jun 30
- Form 8-K Immuneering Corp For: Aug 13
- Form 4 Immuneering Corp For: Jul 02 Filed by: HAUSMAN DIANA
- Form 4 Immuneering Corp For: Jul 02 Filed by: Neufeld Leah R
- Form 4 Immuneering Corp For: Jul 01 Filed by: Zeskind Benjamin J.
- Form 4 Immuneering Corp For: Jun 27 Filed by: Schall Thomas J.
- Form 4 Immuneering Corp For: Jun 20 Filed by: Hall Brett Matthew
- Form 4 Immuneering Corp For: Jun 20 Filed by: Brakewood Harold Eugene
- Form 4 Immuneering Corp For: Jun 18 Filed by: Feinberg Peter
- Form 424B5 Immuneering Corp
- Form 4 Immuneering Corp For: Jun 18 Filed by: Zeskind Benjamin J.
- Form 4 Immuneering Corp For: Jun 17 Filed by: Schall Thomas J.
- Form 8-K Immuneering Corp For: Jun 17
- Form 4 Immuneering Corp For: Jun 13 Filed by: HAUSMAN DIANA
- Form 4 Immuneering Corp For: Jun 13 Filed by: Schall Thomas J.
- Form 4 Immuneering Corp For: Jun 13 Filed by: KEATING LAURIE
- Form 4 Immuneering Corp For: Jun 13 Filed by: Feinberg Peter
- Form 4 Immuneering Corp For: Jun 13 Filed by: CARPENTER ROBERT J
- Form 4 Immuneering Corp For: Jun 13 Filed by: BERMAN ANN E
- Form 8-K Immuneering Corp For: Jun 13
